Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Agata Ptaszynska"'
Autor:
Yiming Li, Jianhua Ma, Jae Hyeon Kim, Agata Ptaszynska, Wenying Yang, June Zhao, Zhiguang Zhou, Yanbing Li
Publikováno v:
Journal of Diabetes. 10:589-599
BACKGROUND This 24-week Phase 3 double-blind placebo-controlled study assessed the safety and efficacy of dapagliflozin as add-on to insulin, with or without oral antihyperglycemic drugs (OADs), in Asian patients with inadequately controlled type 2 d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d289e2229d77bae194d9d287138a875c
https://doi.org/10.1111/1753-0407.12634
https://doi.org/10.1111/1753-0407.12634
Autor:
Agata Ptaszynska, Donald E. Kohan, Kristina Johnsson, Lisa Ying, Paola Fioretto, Shamik Parikh
Publikováno v:
Journal of Nephrology. 29:391-400
Dapagliflozin's antihyperglycemic effects are mediated by inhibition of renal sodium-glucose cotransporter-2; therefore, renal safety of dapagliflozin was assessed.Twelve double-blind, placebo-controlled, randomized clinical trials were analyzed up t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef4ccc22d0644e19d6a994707704647d
https://doi.org/10.1007/s40620-016-0261-1
https://doi.org/10.1007/s40620-016-0261-1
Publikováno v:
Diabetes Therapy
Introduction Hyperkalemia risk is increased in diabetes, particularly in patients with renal impairment or those receiving angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) or potassium-sparing diuretics. Conversely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8000f72205637667a9d29c3a0245c7b2
https://doi.org/10.1007/s13300-015-0150-y
https://doi.org/10.1007/s13300-015-0150-y
Autor:
Nayyar Iqbal, Agata Ptaszynska, Kyung-Wan Min, Ping Han, Caroline T'joen, Bei Wang, Eva Johnsson, Traci A Mansfield, Wenying Yang
Publikováno v:
Journal of Diabetes. 8:796-808
Background Dapagliflozin, a highly selective sodium–glucose cotransporter 2 inhibitor, reduces hyperglycemia, body weight, and blood pressure in patients with type 2 diabetes (T2D). Methods This randomized double-blind placebo-controlled parallel-g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94e059443e1d4116fe8da14053a1e0ab
https://doi.org/10.1111/1753-0407.12357
https://doi.org/10.1111/1753-0407.12357
Publikováno v:
Diabetes, Obesity and Metabolism. 17:809-812
The aim of this study was to investigate the associations between dapagliflozin-mediated reductions in body weight and reductions in glycated haemoglobin (HbA1c) and blood pressure. Data were pooled from seven studies evaluating dapagliflozin 10 mg a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f99ddeb704319ce5bbed7c62871f596f
https://doi.org/10.1111/dom.12500
https://doi.org/10.1111/dom.12500
Publikováno v:
Diabetes and Vascular Disease Research. 12:352-358
The effect of dapagliflozin on blood pressure was evaluated in non-hypertensive (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35af787d844a50488a997f8173bf4463
https://doi.org/10.1177/1479164115585298
https://doi.org/10.1177/1479164115585298
Autor:
Wenying, Yang, Jianhua, Ma, Yiming, Li, Yanbing, Li, Zhiguang, Zhou, Jae Hyeon, Kim, June, Zhao, Agata, Ptaszynska
Publikováno v:
Journal of diabetes. 10(7)
This 24-week Phase 3 double-blind placebo-controlled study assessed the safety and efficacy of dapagliflozin as add-on to insulin, with or without oral antihyperglycemic drugs (OADs), in Asian patients with inadequately controlled type 2 diabetes mel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9b834085b9abd26348fcae9c8a51a61a
https://pubmed.ncbi.nlm.nih.gov/29215189
https://pubmed.ncbi.nlm.nih.gov/29215189
Autor:
Agata Ptaszynska, Kristina Johnsson, Shamik Parikh, James F. List, Tjerk W. A. de Bruin, A. Apanovitch
Publikováno v:
Drug Safety. 37:815-829
Dapagliflozin reduces hyperglycaemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion. This study determined the overall safety profile of dapagliflozin in T2DM. Safety of dapagliflozin in pooled analyses of ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f471b8a103247bb9ed628e6a53af48bc
https://doi.org/10.1007/s40264-014-0213-4
https://doi.org/10.1007/s40264-014-0213-4
Autor:
Kristina Johnsson, James F. List, Bridget Schmitz, Jennifer Sugg, Shamik Parikh, Agata Ptaszynska
Publikováno v:
Journal of Diabetes and its Complications. 27:479-484
Background Vulvovaginitis, balanitis, and related genital infections are common in patients with type 2 diabetes. Glucosuria, which is an outcome of treatment with sodium glucose cotransporter 2 (SGLT2) inhibitors, is among the possible causes. Dapag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2534b03ab16ba5cc78b325ac061d759f
https://doi.org/10.1016/j.jdiacomp.2013.04.012
https://doi.org/10.1016/j.jdiacomp.2013.04.012
Publikováno v:
Postgraduate Medicine. 125:181-189
People with diabetes are more likely to develop a cardiovascular (CV) disease compared with those without diabetes. Although effective glycemic control has been the focus of the management of type 2 diabetes mellitus (T2DM), it is also important to c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::932a97d390a4ae797b908a47d954e7e4
https://doi.org/10.3810/pgm.2013.05.2667
https://doi.org/10.3810/pgm.2013.05.2667